Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Abeona Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H7R vs RCKT, UPB, PALI: FCF Margin % Comparison
For the Biotechnology subindustry, Abeona Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics (LTS:0H7R) has a FCF Margin % of -237.83% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abeona Therapeutics and its competitors. According to the industry distribution chart, Abeona Therapeutics ranks #709 out of 953 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Abeona Therapeutics' FCF Margin % too high?
Abeona Therapeutics' current FCF Margin % is -237.83%. Based on the distribution chart, Abeona Therapeutics ranks #709 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abeona Therapeutics has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' FCF Margin % compare to RCKT and UPB?
According to the Biotechnology industry distribution chart, Abeona Therapeutics ranks #709 out of 953 companies for FCF Margin %. This places Abeona Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current FCF Margin % is -237.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (LTS:0H7R) is currently considered Possible Value Trap. The stock's GF Value™ is $19.19, compared to a current price of $7.17 — trading 62.6% below its estimated fair value. The current FCF Margin % is -237.83%. Abeona Therapeutics' overall GF Score™ is 45/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Abeona Therapeutics (LTS:0H7R), the current FCF Margin % is -237.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (LTS:0H7R) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of $7.17 is trading 62.6% below its estimated GF Value™ of $19.19.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for LTS:0H7R:
FCF Margin %: -237.83%
GF Value™: $19.19 vs. price of $7.17 (62.6% below fair value)
No single metric tells the full story. See the LTS:0H7R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
45GF Score
Get the complete analysis for LTS:0H7R
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H7R has been successfully added to your 
